(Circulation. 2000;101:1372.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
Expression of Angiotensin II and Interleukin 6 in Human Coronary Atherosclerotic Plaques
Potential Implications for Inflammation and Plaque Instability
From the Department of Cardiology (B.S., E.S., D.H.-K., P.T.K., H.D.) and Department of Cardiovascular Surgery (W.H.), Medizinische Hochschule, Hannover, Germany; Wihuri Research Institute (A.H., M.K.), Helsinki, Finland; and the Division D’Hypertension (J.N.), Centre Hospitaliaire Universitaire Vaudois, Suissse.
Correspondence to Helmut Drexler, MD, Department of Cardiology, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, 30625 Hannover, Germany. E-mail Drexler.Helmut{at}MH-Hannover.de
 |
Abstract |
|---|
 Top Abstract IntroductionResultsDiscussionMethodsReferences |
|---|
Background—Patients with an activated renin-angiotensin system (RAS) or genetic alterations of the RAS are at increased risk of myocardial infarction (MI). Administration of ACE inhibitors reduces the risk of MI, and acute coronary syndromes are associated with increased interleukin 6 (IL-6) serum levels. Accordingly, the present study evaluated the expression of angiotensin II (Ang II) in human coronary atherosclerotic plaques and its influence on IL-6 expression in patients with coronary artery disease.
Methods and Results—Immunohistochemical colocalization of Ang II, ACE, Ang II type 1 (AT1) receptor, and IL-6 was examined in coronary arteries from patients with ischemic or dilated cardiomyopathy undergoing heart transplantation (n=12), in atherectomy samples from patients with unstable angina (culprit lesion; n=8), and in ruptured coronary arteries from patients who died of MI (n=13). Synthesis and release of IL-6 was investigated in smooth muscle cells and macrophages after Ang II stimulation. Colocalization of ACE, Ang II, AT1 receptor, and IL-6 with CD68-positive macrophages was observed at the shoulder region of coronary atherosclerotic plaques and in atherectomy tissue of patients with unstable angina. Ang II was identified in close proximity to the presumed rupture site of human coronary arteries in acute MI. Ang II induced synthesis and release of IL-6 shortly after stimulation in vitro in macrophages and rat smooth muscle cells.
Conclusions— Ang II, AT1 receptor, and ACE are expressed at strategic sites of human atherosclerotic coronary arteries, suggesting that Ang II is produced primarily by ACE within coronary plaques. The observation that Ang II induces IL-6 and their colocalization with the AT1 receptor and ACE is consistent with the notion that the RAS may contribute to inflammatory processes within the vascular wall and to the development of acute coronary syndromes.
Key Words: interleukins • angiotensin • angina • myocardial infarction • arteries • receptors
|
Introduction |
|---|
|
TopAbstractIntroductionResultsDiscussionMethodsReferences |
|---|
Rupture of atherosclerotic plaques occurs predominantly at the edges of the plaque’s fibrous cap, the shoulder region, that is, areas of accumulated inflammatory cells, for example, macrophages, T-lymphocytes, and mast cells in close proximity to vascular smooth muscle cells (SMC).1 2 3 4 5 6 The activated inflammatory cells stimulate their neighboring cells to erode the extracellular matrix through the release of inflammatory cytokines. The decay of the framework that forms the plaque cap leads to plaque rupture1 7 8 and resembles the morphological correlate of an acute coronary syndrome. Serum levels of interleukin 6 (IL-6) are increased in patients with unstable angina9 and may trigger the onset of an acute coronary syndrome.10 IL-6 is known to be involved in the stimulation of matrix-degrading enzymes, for example, metalloproteinases.11
In parallel, the renin-angiotensin system (RAS) has been suggested to be involved in the development of acute coronary syndromes, based on the observations that (1) increased circulating levels of renin were associated with a higher incidence of myocardial infarction (MI),12 (2) genetic polymorphisms of the ACE gene revealed a higher risk for coronary events for the ACE/ID phenotype, as compared with the DD-phenotype,13 14 and (3) clinical trials in patients with left ventricular dysfunction demonstrated that long-term ACE inhibition reduces the incidence of MI.15 16
The present study investigated the localization of angiotensin II (Ang II), the Ang II type 1 (AT1) receptor, and ACE within human coronary atherosclerotic plaques. Since IL-6 is increased in patients with acute coronary syndromes, we also investigated whether and how Ang II interacts with IL-6 in vitro and in atherosclerotic plaques of patients with coronary artery disease.
|
Results |
|---|
|
TopAbstractIntroductionResultsDiscussionMethodsReferences |
|---|
In SMC culture, Ang II induced a transient increase of IL-6 transcription (upper transcript) by
7-fold, peaking at 30 minutes
and lasting up to 60 minutes after receptor ligand binding (Figure 1A
). Losartan
(10-5 mol/L), a selective nonpeptide
AT1 antagonist, abolished IL-6 mRNA
increase. Losartan alone or serum-free conditions showed no
effect on IL-6 transcription. Increasing dosages of Ang II caused an
increase in IL-6 transcription up to 3-fold (Figure 1C).
Similarly, Ang II induced a rapid increase in IL-6 transcription in
human macrophages (Figure 1B).
|
Ang II induced IL-6 protein release in the supernatant media that
peaked at 6 hours (Figure 2A).
Losartan completely abolished the IL-6 release. Serum-free
conditions do not stimulate the release of IL-6 (Figure 2A). The
amount of IL-6 release was dose dependent (Figure 2B).
|
In serial sections of the left anterior descending coronary
artery (LAD) obtained from patients with ischemic
cardiomyopathy, atherosclerotic plaques showed a
fibrous cap covering the atherosclerotic material.4
Frequently, the superficial cap at the shoulder region contained
inflammatory infiltrates composed of CD68-positive macrophages
(Figure 3A). When parallel sections were
stained for ACE, Ang II, and AT1 receptor, a
strong positivity corresponding with the sites of macrophage
accumulation (Figure 3, B through D) was found at the shoulder
region. When parallel sections were investigated for IL-6 expression, a
colocalization of IL-6 with macrophage-rich areas was observed
(Figure 3E). Control experiments with the use of an unspecific
IgG as primary antibody revealed no specific staining pattern, as shown
in Figure 3F. Further control experiments with a rabbit
preimmune serum showed also no specific staining pattern (not
shown).
|
Scattered macrophages within the adventitia were positive for Ang II, IL-6, ACE, and AT1 receptor (data not shown). A weak and dispersed positivity for Ang II and IL-6 only was observed in the media. In the adventitia, chymase-containing mast cells identified by chymase staining were found. However, these mast cells were not positive for Ang II or IL-6.
Control experiments with serial sections of the LAD from patients with dilated cardiomyopathy showed no atherosclerotic lesions. In the intima and adventitial layers, only rare and scattered macrophages were found weakly positive for Ang II, AT1 receptor, and IL-6 (not shown). Chymase-containing mast cells were only found scattered within the adventitia. Similar to the atherosclerotic sections, the chymase-containing mast cells did not stain positive for Ang II or IL-6 in any of the coronary sections from patients with dilated cardiomyopathy.
Human coronary plaques from patients with unstable angina were
obtained by directional atherectomy and examined for CD68, Ang II,
AT1 receptor, and IL-6 (Figure 4). CD68-positive cells were frequently
found scattered throughout these tissues and were colocalized with Ang
II, the AT1 receptor, and IL-6 (Figure 4, A through D). The expression of Ang II, the AT1
receptor, and IL-6 appeared to be more pronounced in atherectomy
samples as compared with stable coronary segments. However,
morphometric quantification was not applicable in the
heterogeneous and altered tissue sections because of the
atherectomy procedure. Control experiments with the use of an
unspecific IgG as primary antibody revealed no specific staining
pattern, as shown in Figure 4E.
|
Expression of Ang II was investigated in coronary arteries from
patients who died within 2 days of an acute MI. Coronary
segments containing the presumed ruptured plaque site were isolated and
have been characterized previously.17 Immunohistochemical
results revealed that in close proximity of the presumed plaque rupture
site, Ang II is accumulated (Figure 5).
Chymase-containing mast cells were not present. Comparison of
adjacent sections revealed that the chymase-containing mast cells did
not contain Ang II.
|
|
Discussion |
|---|
|
TopAbstractIntroductionResultsDiscussionMethodsReferences |
|---|
The present study demonstrates that Ang II, the AT1 receptor, and ACE are expressed at strategically relevant sites of human coronary atherosclerotic plaques in the shoulder region. These findings suggest that ACE is the major Ang II–forming enzyme in atherosclerotic human coronary arteries. Moreover, Ang II was detected in close proximity to the presumed plaque rupture site in coronary artery sections from patients who died acutely after MI. Colocalization of components of the RAS with IL-6 was observed in stable coronary plaques and atherectomy tissues, and Ang II induced the expression of IL-6 in vitro, both in macrophages and in SMC. These findings are consistent with the notion that the RAS may contribute to inflammatory processes within the atherosclerotic vascular wall and to the development of acute coronary syndromes.
Recent observations indicated that the RAS plays an important role in the progression of atherosclerosis and in the development of acute coronary syndromes.12 13 14 15 16 Clinical trials reported that administration of ACE inhibitors after MI reduced not only the cumulative incidence of heart failure but also the incidence of reoccurrence of MI.15 16 These observations support the hypothesis that Ang II, generated by ACE, may contribute to the progression of atherosclerosis and potentially to the disruption of coronary plaques. Experimental studies revealed further that ACE inhibitors might exert antiatherogenic and antiproliferative effects in the vascular wall.18 19 20 21
We demonstrated that Ang II is expressed in stable, unstable, and ruptured human coronary plaques. Similarly, there is evidence that Ang II is expressed in atherosclerotic lesions in primates.22 Recent observations indicate that ACE is expressed in human atherosclerotic plaques in areas of clustered macrophages.23 Importantly, macrophage-rich areas are more abundant in human atherosclerotic coronary arteries of patients with unstable angina and non–Q-wave infarction as compared with stable atherosclerotic plaques.24 Therefore Ang II expression might be enhanced in unstable plaques as compared with stable coronary plaques. Together with the vast abundance of ACE, Ang II, and CD68-positive macrophages and only the few chymase-containing mast cells, it is conceivable that ACE in macrophages is the primary Ang II–forming pathway in human atherosclerotic plaques. In this regard, preliminary findings suggest that ACE but not chymase generates Ang II in isolated human coronaries.25
Ang II may be involved in the development of an acute
coronary syndrome, based on the observations that (1) Ang II
may increase biomechanical stress at the shoulder of atherosclerotic
lesions26 and (2) the site of plaque rupture is
characterized by an inflammatory process and an accumulation of
macrophages.4 23 24 The present study
demonstrated that IL-6 is expressed in areas of clustered
macrophages colocalized with Ang II and that Ang II induces
IL-6 expression in macrophages in vitro. Although IL-6 is
thought to be an anti-inflammatory cytokine, recent
observations emphasized the proinflammatory potency of IL-6 as a
central regulator of inflammation and macrophage
differentiation.9 IL-6 induces the expression of
acute-phase proteins in SMC27 28 and the migration and
differentiation of activated
macrophages.11 29 IL-6 may contribute to the
development of an acute coronary syndrome by stimulating the
synthesis of matrix degrading enzyme7 and LDL receptors in
macrophages and the stimulation of LDL-uptake in
macrophages.30 Moreover, IL-6 activates
macrophages to secrete monocyte chemotactic
protein-1,28 pivotal for monocyte recruitment into tissues
and a central mediator of inflammatory events in
atherosclerosis.28 29 30 31 32 Finally, IL-6
regulates the expression of adhesion molecules and other
cytokines, for example, IL-1ß and tumor necrosis
factor-
,11 27 31 which potentially enhance the
inflammatory reaction.31
The present study demonstrated (1) that Ang II stimulates the synthesis and release of IL-6 in vitro and (2) the colocalization of both factors in vivo at the shoulder region of coronary plaques. These observations may point to Ang II as a potential modulator of inflammatory processes that occur chronically at the shoulder region of atherosclerotic coronary plaques. It is conceivable, therefore, that these 2 factors interact and thereby amplify the development of an acute coronary syndrome.
Furthermore, Ang II may contribute to the development of an acute coronary syndrome through the migration of macrophages into a neointimal area33 or by producing reactive oxygen species and thereby increasing oxidative stress.34 Increased secretion of macrophage-derived interleukins was observed in cells exposed to oxidative stress, such as oxidized LDL or cellular lipid peroxidation induced by iron ions.35 In contrast, administration of ACE inhibitors abolished macrophage recruitment in this experimental model,36 37 and blockade of the AT1 receptor by losartan was shown to prevent the accumulation of oxidative reactants, which abolished lipid peroxidation and the progression of atherosclerosis in an apolipoprotein E–deficient animal model.38 39
The present study may have potential clinical implications by pointing to mechanisms by which ACE inhibitors reduce the incidence of reinfarctions, that is, the attenuation of proinflammatory processes in atherosclerotic plaques. If so, ACE inhibition should reduce serum markers of inflammation in patients treated with ACE inhibitors. Preliminary observations indicated that long-term ACE inhibition reduces circulating levels of C-reactive protein in patients with coronary artery disease.40 These findings are consistent with the notion that an interaction between the RAS and proinflammatory cytokines occurs, which may affect the balance between stabilizing and destabilizing factors at the fibrous cap and thereby promote the instability of a former stable coronary plaque.
Study Limitations
Our analysis of coronary arteries obtained during
transplantation reveals that chymase-containing mast cells are
consistently seen in the adventitia but did not stain for Ang
II. We cannot exclude that chymase secreted by activated mast
cells provides an alternative pathway for Ang II
formation,41 but cellular colocalization and abundance of
Ang II in macrophage-rich areas suggests that mast
cell–derived chymase is not the major contributor of Ang II formation
in human atherosclerotic coronary arteries.
Second, diffusion of Ang II from its areas of generation cannot be excluded but rather would be explained by the metabolism of ACE. As a transmembrane enzyme with its extracellular catalytic domain, some ACE is cleaved from the plasma membrane and appears as a catalytically active ACE in the extracellular space. This would explain the diffuse staining pattern of ACE and Ang II.
|
Methods |
|---|
|
TopAbstractIntroductionResultsDiscussionMethodsReferences |
|---|
Materials
Media, Superscript, and TriZol were from GIBCO Laboratories. IL-6 antibody was from R&D Systems (clone SF642 ); ACE antibody (clone 9B9, BioTrack Inc) and CD68 antibody (Ber-MAC3; DAKO Inc) also were used. Polyclonal AT1 antibody was from Santa Cruz Biotech. The Ang II antibody (clone No. 79s) was characterized by one of the authors (J.N., Reference 4343 ). Anti-chymase antibody (clone No. MAB1254) was obtained from Chemicon Inc. Ang II, secondary antibodies, and all chemicals were purchased from Sigma.
Cell Culture
Rat aortic SMC were maintained in DMEM supplemented with
10% (vol/vol) fetal bovine serum, 10 µg/mL streptomycin, and 100
U/mL penicillin. Cells were grown to 75% to 85% confluence and serum
starved for 24 hours.44 Human macrophages were
isolated by Ficoll gradient centrifugation, maintained
in RPMI/M-199, and serum-starved for 18 hours before use. Ang II
(10-7 mol/L), lipopolysaccharides (10
µg/mL), and losartan (10-5 mol/L) were
added to the media, and IL-6 expression and release was determined as
indicated.
Tissue Preparation
Samples of coronary arteries were obtained from
recipient hearts removed at transplantation surgery (n=5 patients with
ischemic cardiomyopathy, age 55±5 years).
Coronary artery segments from patients with idiopathic dilated
cardiomyopathy were used as control (n=9, age 43±9
years). Ten segments from each major coronary artery, right
coronary artery, LAD, and circumflex branch of the left
coronary artery were examined. Artery segments were collected
at the time of heart transplantation. Vessels were perfused with
ice-cold PBS, dissected from the myocardium, and embedded
in OCT compound (Miles Laboratories), frozen in isopentane, cooled in
liquid nitrogen, and stored at -80°C. Specimens from 8 patients with
LAD lesions and unstable angina (Braunwald classification IIB and IIC)
were obtained by directional atherectomy (culprit lesion, single-vessel
disease, Simpson Athero Cath), embedded in OCT, and kept at -80°C.
Serial sections (6 µm) were mounted onto slides and stored at
-20°C. Samples of coronary arteries were isolated at autopsy
from 13 subjects who died after acute MI.17 The slides
were fixed in Carnoy’s fluid (60% ethanol, 30% chloroform, and 10%
glacial acetic acid) for 24 hours and embedded in
paraffin.17 Coronary sections were rehydrated and
used for immunohistochemistry. Because of the limited amount of
material available and specific fixation procedure, sections from these
coronary artery sections were assayed for Ang II expression
only.
Immunohistochemical Analysis
Serial sections from atherectomy tissues and coronary
arteries were mounted, and endogenous peroxidase was
blocked by immersion in 3% hydrogen peroxide for 15 minutes before the
primary antibody was used (antibody concentrations: IL-6 1:500, ACE
1:100, AT1 1:800, CD68 1:250, Ang II 1:500). The
antibody concentrations were tested in lung tissue samples from
patients who died of bacterial pneumonia. All antisera clearly
demonstrated their staining specificity, whereas unspecific anti-mouse
IgG or anti-rabbit IgG showed no unspecific staining pattern. The
peroxidase diaminobenzidine reaction showed no unspecific staining
pattern (data not shown). The primary antibody was applied for 3 hours,
followed by streptavidin-biotin complex immunoperoxidase reaction
(LSAB2-kit, DAKO) with diaminobenzidine. The final reaction product
was visualized by a brownish color. The sections were counterstained
with hematoxylin and mounted under coverslips. Unspecific mouse or
rabbit IgG antibody were used as negative controls.
Protein Analysis
IL-6 protein concentration was determined by ELISA in the
supernatant media. The supernatant probes were then processed,
following the instructions of the manufacturer. The results were
determined by spectrophotometry at 420 nm. Data were transferred and
statistically processed (Sigma-Plot, Jandel Inc).
Northern Blot Analysis
Total RNA was separated by gel electrophoresis and blotted onto
membranes (Hybond-N+, Amersham). cDNA probes for
IL-6, generated by polymerase chain reaction (PCR) (rat: 533 bp,
5'-TGTTGTTGACAGCCACTGC-3' and 5'-TTTCAAGATGAGTT- GGATGGTC-3'), were
labeled with a DNA-labeling kit (Boehringer Mannheim). Blots
were visualized by PhosphorImager (FujiBas 1000) and
autoradiography. Dose-response curves were quantified
by image analysis (Gel BioDoc 2000, Bio-Rad).
Reverse Transcriptase–PCR
Total RNA was isolated from human macrophages with the
use of TriZol (GIBCO BRL). First-strand synthesis was
carried out with total cDNA with the use of reverse-transcriptase and
oligo d(T) primers. Semiquantitative PCR was carried out by normalizing
all cDNAs to GAPDH. Primer sequences for human IL-6, 628 bp, were
5'-ATGAACTCCTTCTCCACAAGCGC-3' and 5'-GAAGAGCC- CTCAGGCTGGACTG-3'.
All cDNAs were tested for equal amounts of GAPDH by PCR (Biometra). PCR
fragments were densitometrically analyzed (GelDoc 2000,
Bio-Rad). Data are given as mean±SEM.
|
Acknowledgments |
|---|
This study was supported by the Deutsche Forschungsgemeinschaft grants Dr 142/6-4 and Schie 386/3-1. The authors are indebted to Silvia Gutzke and Nicole Brauer for excellent technical assistance; Jan Galle, University of Wuerzburg, Germany, for providing the macrophage cell culture; and T. Paavonen, University of Helsinki, for providing coronary artery slides of patients who died of acute MI.
|
Footnotes |
|---|
The Methods section of this article can be found at http://www.circulationaha.org
Received July 8, 1999; revision received October 12, 1999; accepted October 21, 1999.
|
References |
|---|
|
TopAbstractIntroductionResultsDiscussionMethodsReferences |
|---|
1. Libby P. Molecular bases of the acute coronary syndrome. Circulation. 1995;21 2844–2850.
2.
Davies MJ, Thomas AC. Plaque fissuring: the
cause of acute myocardial infarction, sudden ischemic death,
and crescendo angina. Br Heart J. 1985;53:363–373.
3. Ross R. Pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801–809.[Medline] [Order article via Infotrieve]
4. Van der Waal AC, Becker AE, Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:34–44.
5.
Jonasson L, Holm J, Skalli O, Bondjers G,
Hansson GK. Regional accumulation of T-cells, macrophages, and
smooth muscle cells in the human atherosclerotic plaque.
Arteriosclerosis. 1986;6:131–138.
6.
Kaartinen M, Penttilä A, Kovanen PT.
Accumulation of mast cells in the shoulder region of human
atheroma, the predilection site of
atheromatous rupture. Circulation. 1994;90:1669–1678.
7.
Galis ZS., Muszynski M, Sukhova GK,
Simon-Morrissey E, Unemori EN, Lark M, Amento E, Libby P.
Cytokine-stimulated smooth muscle cells stimulate a complement
of enzymes required for extracellular matrix digestion. Circ
Res. 1994;75:181–189.
8.
Kaartinen M, Penttilä A, Kovanen PT. Mast
cells in the rupture-prone areas of human coronary
atheromas produce and store TNF.
Circulation. 1996;94:2787–2792.
9.
Biassuci L, Vitelli A, Liuzzo G, Altamura S,
Caliguri G, Monaco C, Rebuzzi A, Ciliberto G, Maseri A. Elevated levels
of interleukin-6 in unstable angina. Circulation. 1996;94:874–877.
10. Marx N, Neumann FJ, Ott I, Gawaz M, Koch W, Pikau T, Schömig A. Induction of cytokine expression in leucocytes in acute myocardial infarction. J Am Coll Cardiol. 1997;30:165–170.[Abstract]
11.
Kishimoto T, Akira S, Narazaki M, Taga T.
Interleukin 6 family of cytokines and gp130. Blood. 1995;86:1243–1254.
12. Aldermann MH, Madhavan S, Ooi WL, Cohen H, Sealy JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098–1104.[Abstract]
13.
Cambien F, Costerousse O, Tirret L, Poirier O,
Lecerf L, Gonzales MF, Evans A, Arveilier D, Cambou JP, Luc G,
Rakotovao R, Ducimetiere P, Sourbrier F, Alhenc-Gelas F. Plasma levels
and gene polymorphism of angiotensin converting enzyme
in relation to myocardial infarction. Circulation. 1994;90:669–676.
14. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arvelier D, Luc G, Bard JM, Bara R, Richard S, Tiret L, Amouyel P, Alhenc-Gelas F, Sourbrier F. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992;359:641–644.[Medline] [Order article via Infotrieve]
15. Pfeffer M, Braunwald E, Moye L, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltmann EM, Goldman S, Flaker GC, Klein M, Lamas G, Packer M, Rouleau J, Rutherford J, Wertheimer JH, Hawkins CM. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med. 1992;327:669–677.[Abstract]
16. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction. N Engl J Med. 1992;327:568–574.[Medline] [Order article via Infotrieve]
17.
Kovanen PT, Kaartinen M, Paavonen T. Infiltrates
of activated mast cells at the site of coronary
atheromatous erosion or rupture in myocardial
infarction. Circulation. 1995;92:1084–1088.
18. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol. 1990;15(suppl I):S65–S72.
19.
Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM.
Angiotensin II induces smooth muscle cell proliferation in
the normal and injured rat arterial wall. Circ
Res. 1991;68:450–456.
20.
Powell JS, Clozel JP, Müller RK, Kuhn H,
Heft F, Hosning M. Inhibitors of angiotensin
converting enzyme prevent myointimal proliferation after vascular
injury. Science. 1989;245:186–188.
21.
Chobanian AV, Haudenschild CC, Nickerson C, Hope
S. Trandolapril inhibits atherosclerosis in Watanabe
heritable hyperlipidemic rabbits.
Hypertension. 1992;20:473–477.
22.
Potter DD, Sobey CG, Tompkins PK, Rossen JD,
Heistad DD. Evidence that macrophages in atherosclerotic
lesions contain angiotensin II. Circulation. 1998;98:800–807.
23.
Diet F, Pratt R, Berry GJ, Momose N, Gibbons G,
Dzau VJ. Increased accumulation of tissue ACE in human
atherosclerotic coronary artery disease.
Circulation. 1996;94:2756–2767.
24.
Moreno PR, Falk E, Palaicos IF, Newell JB, Fuster
V, Fallon JT. Macrophage infiltration in acute coronary
syndromes. Implications for plaque rupture. Circulation. 1994;90:775–778.
25. Massenvandenbrink A, de Vries R, Danser AH. ACE but not chymase generates angiotensin II in close proximity to the AT1-receptor in human isolated coronary arteries. Circulation. 1998;98(suppl I):I-606. Abstract.
26.
Loree HM, Kamm RD, Stringfellow RG, Lee RT.
Effects of fibrous cap thickness on peak circumferential stress in
model atherosclerotic vessels. Circ Res. 1992;71:850–858.
27. Ikeda U, Ikeda M, Seino Y, Takahashi M, Kasahara T, Kano S, Shimada K. Expression of intracellular adhesion molecule 1 in rat vascular smooth muscle cells by pro-inflammatory cytokines. Atherosclerosis. 1993;104:61–68.[Medline] [Order article via Infotrieve]
28.
Biswas P, Delfanti F, Mengozzi M, Cota M,
Polentarutti N, Matnovani A, Lazzarin A, Sozzani S, Poli G. Interleukin
6 induces monocyte chemotactic protein-1 in peripheral
blood mononuclear cells and in the U937 cell line. Blood. 1998;91:258–265.
29. Bacon K, Gearing A, Camp R. Induction of in-vitro human lymphocyte migration by interleukin 3, interleukin-4, and interleukin 6. Cytokine. 1990;2:100–105.[Medline] [Order article via Infotrieve]
30.
Hamanak R, Kohno K, Seguchi T, Okamura K,
Morimoto T, Onon M, Ogata M, Kuwano M. Induction of low-density
lipoprotein receptor and transcription factor SP-1 by tumor necrosis
factor in human vascular endothelial cells.
J Biol Chem. 1992;267:13160–13165.
31. Montavi A. The interplay between primary and secondary cytokines. Cytokines involved in the regulation of monocyte recruitment. Drugs. 1997;97(suppl I)15–23.
32. Boring L, Gosling J, Cleary M, Charo I. Decreased lesion formation in CCR2 -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394:894–897.[Medline] [Order article via Infotrieve]
33. Weinstock JV, Blum AM, Kassab JT. Angiotensin II is chemotactic for a T-cell subset which can express migration inhibitory factor activity in urine schistosomiasis mansoni. Cell Immunol. 1987;107:180–187.[Medline] [Order article via Infotrieve]
34.
Pagano PJ, Clark JK, Cifuentes-Pagano ME, Clark
SM, Callis GM, Quinn MT. Localization of a constitutively active,
phagocyte-like NADPH oxidase in rabbit aortic smooth adventitia:
enhancement by angiotensin II. Proc Natl Acad Sci
U S A. 1997;94:14483–14488.
35. Aviram M. Oxidative modification of low density lipoprotein and its relation to atherosclerosis. Isr J Med Sci. 1995;31:241–249.[Medline] [Order article via Infotrieve]
36.
Hernandez-Presa M, Bustos C, Ortego M, Tunon J,
Renendo J, Ruiz-Ortega M, Egido J, Angiotensin-converting
enzyme inhibition prevents arterial nuclear
factor-
B activation, monocyte chemoattractant protein-1
expression, and macrophage infiltration in a rabbit model of
early accelerated atherosclerosis.
Circulation. 1997;95:1532–1541.
37. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein and atherogenesis. J Clin Invest. 1991;88:1785–1792.
38. Keidar S, Kaplan M, Hofman A, Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low-density lipoproteins. Atherosclerosis. 1995;115:201–215.[Medline] [Order article via Infotrieve]
39. Keidar S, Attias J, Smith J, Breslow J, Hayek T. The angiotensin II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997;236:622–625.[Medline] [Order article via Infotrieve]
40. Erikson SV, Kjekhuis J, Eneroth P, Swedberg K. Neopterin, tumor necrosis factor C-reactive protein and prostaglandin E2 in patients with severe congestive heart failure treated with enalapril. Circulation. 1997;97(suppl I):I-322. Abstract.
41.
Kokoonen JO, Saarinen J, Kovanen PT. Regulation
of local angiotensin II formation in the human heart in the
presence of interstitial fluid and of
angiotensin-converting enzyme by Ang-(1–9) formed by heart
carboxypeptidase A-like activity. Circulation. 1997;95:1455–1463.
42. Shanley TP, Foreback JL, Remick DG, Ullich TR, Kunkel SL, Ward PA. Regulatory effect of interleukin-6 in immunoglobulin G immune-complex-induced lung injury. Am J Pathol. 1997;151:193–203.[Abstract]
43. Nussberger J, Keller I, Waeber B, Brunner HR. Angiotensin II measurement with high affinity monoclonal antibodies. J Hypertens. 1988;6:S424–S425.
44.
Schieffer B, Paxton WG, Marrero MB, Bernstein KE.
Importance of tyrosine phosphorylation in
Angiotensin II AT1 receptor mediated
signaling. Hypertension. 1996;27:476–480.
This article has been cited by other articles:
 |
|
 |
|
  A. GLUBA, M. BANACH, D. P. MIKHAILIDIS, and J. RYSZ Genetic Determinants of Cardiovascular Disease: The Renin-Angiotensin-Aldosterone System, Paraoxonases, Endothelin-1, Nitric Oxide Synthase and Adrenergic Receptors In Vivo, September 1, 2009; 23(5): 797 - 812. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Cianci, A. Gigante, L. Polidori, D. Di Donato, P. Martina, B. Barbano, R. Renzulli, A. Zaccaria, and G. Fuiano In-Stent Restenosis of the Renal Artery in a Single Kidney Patient: The Role of ACEI in the Therapeutic Choice Angiology, August 1, 2009; 60(4): 496 - 503. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Ortiz-Munoz, J. L. Martin-Ventura, P. Hernandez-Vargas, B. Mallavia, V. Lopez-Parra, O. Lopez-Franco, B. Munoz-Garcia, P. Fernandez-Vizarra, L. Ortega, J. Egido, et al. Suppressors of Cytokine Signaling Modulate JAK/STAT-Mediated Cell Responses During Atherosclerosis Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 525 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Hao, L. Wang, and H. Tang Vascular endothelial growth factor induces protein kinase D-dependent production of proinflammatory cytokines in endothelial cells Am J Physiol Cell Physiol, April 1, 2009; 296(4): C821 - C827. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cambronero, F. Marin, V. Roldan, D. Hernandez-Romero, M. Valdes, and G. Y.H. Lip Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis Eur. Heart J., January 9, 2009; (2009) ehn538v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Fang, D. G. Oreopoulos, and J. M. Bargman Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3704 - 3710. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hudorovic eComment: Statins and ACE-inhibitors Interactive CardioVascular and Thoracic Surgery, August 1, 2008; 7(4): 581 - 581. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Tamagawa, N. Bai, K. Morimoto, C. Gray, T. Mui, K. Yatera, X. Zhang, L. Xing, Y. Li, I. Laher, et al. Particulate matter exposure induces persistent lung inflammation and endothelial dysfunction Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L79 - L85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Loppnow, K. Werdan, and M. Buerke Invited review: Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms Innate Immunity, April 1, 2008; 14(2): 63 - 87. [Abstract] [PDF]
|
|
|
|
|
|
G. T. Jones, A. R. Thompson, F. M. van Bockxmeer, H. Hafez, J. A. Cooper, J. Golledge, S. E. Humphries, P. E. Norman, and A. M. van Rij Angiotensin II Type 1 Receptor 1166C Polymorphism Is Associated With Abdominal Aortic Aneurysm in Three Independent Cohorts Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 764 - 770. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Takata, J. Liu, F. Yin, A. R. Collins, C. J. Lyon, C.-H. Lee, A. R. Atkins, M. Downes, G. D. Barish, R. M. Evans, et al. PPAR{delta}-mediated antiinflammatory mechanisms inhibit angiotensin II-accelerated atherosclerosis PNAS, March 18, 2008; 105(11): 4277 - 4282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. F.H. Mueller and G. Nickenig Angiotensin II: One Driving Force Behind Atherogenesis Hypertension, February 1, 2008; 51(2): 175 - 176. [Full Text] [PDF]
|
|
|
|
|
|
L. I. Schrader, D. A. Kinzenbaw, A. W. Johnson, F. M. Faraci, and S. P. Didion IL-6 Deficiency Protects Against Angiotensin II Induced Endothelial Dysfunction and Hypertrophy Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2576 - 2581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Tso, J. G. Merino, and S. Warach Interleukin-6 174G/C Polymorphism and Ischemic Stroke: A Systematic Review Stroke, November 1, 2007; 38(11): 3070 - 3075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Heeneman, J. C. Sluimer, and M. J.A.P. Daemen Angiotensin-Converting Enzyme and Vascular Remodeling Circ. Res., August 31, 2007; 101(5): 441 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H.H. Feringa, S. E. Karagiannis, M. Chonchol, R. Vidakovic, P. G. Noordzij, A. Elhendy, R. T. van Domburg, G. Welten, O. Schouten, J. J. Bax, et al. Lower Progression Rate of End-Stage Renal Disease in Patients with Peripheral Arterial Disease Using Statins or Angiotensin-Converting Enzyme Inhibitors J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1872 - 1879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kapoor Interleukin-6 Antagonists for the Management of Hypertension Hypertension, March 1, 2007; 49(3): e18 - e18. [Full Text] [PDF]
|
|
|
|
|
|
W. Koenig and N. Khuseyinova Biomarkers of Atherosclerotic Plaque Instability and Rupture Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 15 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Suzuki, M. Saito, T. Nagai, H. Saeki, and Y. Kazatani Systemic Versus Coronary Levels of Inflammation in Acute Coronary Syndromes Angiology, August 1, 2006; 57(4): 459 - 463. [Abstract] [PDF]
|
|
|
|
|
|
C. Ulrich, G. H. Heine, P. Garcia, B. Reichart, T. Georg, M. Krause, H. Kohler, and M. Girndt Increased expression of monocytic angiotensin-converting enzyme in dialysis patients with cardiovascular disease Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1596 - 1602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Takeda, I. Manabe, T. Shindo, H. Iwata, S. Iimuro, H. Kagechika, K. Shudo, and R. Nagai Synthetic Retinoid Am80 Reduces Scavenger Receptor Expression and Atherosclerosis in Mice by Inhibiting IL-6 Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 1177 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chon, M. C. Verhaar, H. A. Koomans, J. A. Joles, and B. Braam Role of Circulating Karyocytes in the Initiation and Progression of Atherosclerosis Hypertension, May 1, 2006; 47(5): 803 - 810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ribichini, F. Pugno, V. Ferrero, G. Bussolati, M. Feola, P. Russo, C. Di Mario, A. Colombo, and C. Vassanelli Cellular Immunostaining of Angiotensin-Converting Enzyme in Human Coronary Atherosclerotic Plaques J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1143 - 1149. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H.H. Feringa, V. H. van Waning, J. J. Bax, A. Elhendy, E. Boersma, O. Schouten, W. Galal, R. V. Vidakovic, M. J. Tangelder, and D. Poldermans Cardioprotective Medication Is Associated With Improved Survival in Patients With Peripheral Arterial Disease J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1182 - 1187. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Armstrong, D. A. Morrow, and M. S. Sabatine Inflammatory Biomarkers in Acute Coronary Syndromes: Part I: Introduction and Cytokines Circulation, February 14, 2006; 113(6): e72 - e75. [Full Text] [PDF]
|
|
|
|
 |
|
 D M Shavelle Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis? Heart, October 1, 2005; 91(10): 1257 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Pemberton, S. D. Raudsepp, T. G. Yandle, V. A. Cameron, and A. M. Richards Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch Cardiovasc Res, October 1, 2005; 68(1): 109 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Antoniades, D. Tousoulis, C. Vasiliadou, C. Pitsavos, C. Chrysochoou, D. Panagiotakos, C. Tentolouris, K. Marinou, N. Koumallos, and C. Stefanadis Genetic Polymorphism on Endothelial Nitric Oxide Synthase Affects Endothelial Activation and Inflammatory Response During the Acute Phase of Myocardial Infarction J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1101 - 1109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Munzel, A. Daiber, V. Ullrich, and A. Mulsch Vascular Consequences of Endothelial Nitric Oxide Synthase Uncoupling for the Activity and Expression of the Soluble Guanylyl Cyclase and the cGMP-Dependent Protein Kinase Arterioscler Thromb Vasc Biol, August 1, 2005; 25(8): 1551 - 1557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zampetaki, Z. Zhang, Y. Hu, and Q. Xu Biomechanical stress induces IL-6 expression in smooth muscle cells via Ras/Rac1-p38 MAPK-NF-{kappa}B signaling pathways Am J Physiol Heart Circ Physiol, June 1, 2005; 288(6): H2946 - H2954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Esteban, M. Ruperez, E. Sanchez-Lopez, J. Rodriguez-Vita, O. Lorenzo, H. Demaegdt, P. Vanderheyden, J. Egido, and M. Ruiz-Ortega Angiotensin IV Activates the Nuclear Transcription Factor-{kappa}B and Related Proinflammatory Genes in Vascular Smooth Muscle Cells Circ. Res., May 13, 2005; 96(9): 965 - 973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Kritchevsky, M. Cesari, and M. Pahor Inflammatory markers and cardiovascular health in older adults Cardiovasc Res, May 1, 2005; 66(2): 265 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Furnkranz, A. Schober, V. N. Bochkov, P. Bashtrykov, G. Kronke, A. Kadl, B. R. Binder, C. Weber, and N. Leitinger Oxidized Phospholipids Trigger Atherogenic Inflammation in Murine Arteries Arterioscler Thromb Vasc Biol, March 1, 2005; 25(3): 633 - 638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wellner, R. Dechend, J.-K. Park, E. Shagdarsuren, N. Al-Saadi, T. Kirsch, P. Gratze, W. Schneider, S. Meiners, A. Fiebeler, et al. Cardiac gene expression profile in rats with terminal heart failure and cachexia Physiol Genomics, February 10, 2005; 20(3): 256 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Madamanchi, A. Vendrov, and M. S. Runge Oxidative Stress and Vascular Disease Arterioscler Thromb Vasc Biol, January 1, 2005; 25(1): 29 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Daugherty, D. L. Rateri, H. Lu, T. Inagami, and L. A. Cassis Hypercholesterolemia Stimulates Angiotensin Peptide Synthesis and Contributes to Atherosclerosis Through the AT1A Receptor Circulation, December 21, 2004; 110(25): 3849 - 3857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Helske, K. A. Lindstedt, M. Laine, M. Mayranpaa, K. Werkkala, J. Lommi, H. Turto, M. Kupari, and P. T. Kovanen Induction of local angiotensin II-producing systems in stenotic aortic valves J. Am. Coll. Cardiol., November 2, 2004; 44(9): 1859 - 1866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rosenhek, F. Rader, N. Loho, H. Gabriel, M. Heger, U. Klaar, M. Schemper, T. Binder, G. Maurer, and H. Baumgartner Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis Circulation, September 7, 2004; 110(10): 1291 - 1295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Schieffer, C. Bunte, J. Witte, K. Hoeper, R. H. Boger, E. Schwedhelm, and H. Drexler Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease J. Am. Coll. Cardiol., July 21, 2004; 44(2): 362 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Smith, A. Yndestad, B. Halvorsen, T. Ueland, T. Waehre, K. Otterdal, H. Scholz, K. Endresen, L. Gullestad, S. S. Froland, et al. Potential anti-inflammatory role of activin A in acute coronary syndromes J. Am. Coll. Cardiol., July 21, 2004; 44(2): 369 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Neri Serneri, M. Boddi, P. A. Modesti, M. Coppo, I. Cecioni, T. Toscano, M. L. Papa, M. Bandinelli, G. F. Lisi, and M. Chiavarelli Cardiac Angiotensin II Participates in Coronary Microvessel Inflammation of Unstable Angina and Strengthens the Immunomediated Component Circ. Res., June 25, 2004; 94(12): 1630 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Tsunemi, S. Takai, M. Nishimoto, D. Jin, M. Sakaguchi, M. Muramatsu, A. Yuda, S. Sasaki, and M. Miyazaki A Specific Chymase Inhibitor, 2-(5-Formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[{3,4-dioxo-1-phenyl-7-(2-pyridyloxy)}-2-heptyl]acetamide (NK3201), Suppresses Development of Abdominal Aortic Aneurysm in Hamsters J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 879 - 883. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yousufuddin, D. J. Cook, R. C. Starling, A. Abdo, P. Paul, E. M. Tuzcu, N. B. Ratliff, P. M. McCarthy, J. B. Young, and M. H. Yamani Angiotensin II receptors from peritransplantation through first-year post-transplantation and the risk of transplant coronary artery disease J. Am. Coll. Cardiol., May 5, 2004; 43(9): 1565 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H.P. Hilgers, P. M.H. Schiffers, W. M. Aartsen, G. E. Fazzi, J. F.M. Smits, and J. G.R. De Mey Tissue Angiotensin-Converting Enzyme in Imposed and Physiological Flow-Related Arterial Remodeling in Mice Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 892 - 897. [Abstract] [Full Text]
|
|
|
|
|
|
F. Cipollone, M. Fazia, A. Iezzi, B. Pini, C. Cuccurullo, M. Zucchelli, D. de Cesare, S. Ucchino, F. Spigonardo, M. De Luca, et al. Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E2-Dependent Matrix Metalloproteinase Activity Circulation, March 30, 2004; 109(12): 1482 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wassmann, M. Stumpf, K. Strehlow, A. Schmid, B. Schieffer, M. Bohm, and G. Nickenig Interleukin-6 Induces Oxidative Stress and Endothelial Dysfunction by Overexpression of the Angiotensin II Type 1 Receptor Circ. Res., March 5, 2004; 94(4): 534 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yousufuddin, S. Haji, R. C. Starling, E. M. Tuzcu, N. B. Ratliff, D. J. Cook, A. Abdo, Y. Saad, S. S. Karnik, D. Wang, et al. Cardiac angiotensin II receptors as predictors of transplant coronary artery disease following heart transplantation Eur. Heart J., March 1, 2004; 25(5): 377 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamagami, K. Kitagawa, Y. Nagai, H. Hougaku, M. Sakaguchi, K. Kuwabara, K. Kondo, T. Masuyama, M. Matsumoto, and M. Hori Higher Levels of Interleukin-6 Are Associated With Lower Echogenicity of Carotid Artery Plaques Stroke, March 1, 2004; 35(3): 677 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Mehta, B. Hu, J. Chen, and D. Li Pioglitazone Inhibits LOX-1 Expression in Human Coronary Artery Endothelial Cells by Reducing Intracellular Superoxide Radical Generation Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2203 - 2208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Di Napoli and F. Papa Association Between Blood Pressure and C-Reactive Protein Levels in Acute Ischemic Stroke Hypertension, December 1, 2003; 42(6): 1117 - 1123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Silvestro, F. Scopacasa, A. Ruocco, G. Oliva, V. Schiano, C. Zincarelli, and G. Brevetti Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease Vascular Medicine, November 1, 2003; 8(4): 225 - 232. [Abstract] [PDF]
|
|
|
|
|
|
A. T Hirsch and D. Duprez The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease Vascular Medicine, November 1, 2003; 8(4): 273 - 278. [Abstract] [PDF]
|
|
|
|
|
|
M. Girndt and H. Kohler Interleukin-10 (IL-10): an update on its relevance for cardiovascular risk Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1976 - 1979. [Full Text] [PDF]
|
|
|
|
|
|
L. J Wagenaar, A. J van Boven, A. C van der Wal, G. Amoroso, R. A Tio, C. M van der Loos, A. E Becker, and W. H van Gilst Differential localisation of the renin-angiotensin system in de-novo lesions and in-stent restenotic lesions in in-vivo human coronary arteries Cardiovasc Res, October 1, 2003; 59(4): 980 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jones, S. S. Dhamrait, J. R. Payne, E. Hawe, P. Li, I. S. Toor, L. Luong, P. T.E. Wootton, G. J. Miller, S. E. Humphries, et al. Genetic Variants of Angiotensin II Receptors and Cardiovascular Risk in Hypertension Hypertension, October 1, 2003; 42(4): 500 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Kato, K. Dote, S. Habara, H. Takemoto, K. Goto, and K. Nakaoka Clinical implications of carotid artery remodeling in acute coronary syndrome: Ultrasonographic assessment of positive remodeling J. Am. Coll. Cardiol., September 17, 2003; 42(6): 1026 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Koh, J. Y. Ahn, S. H. Han, D. S. Kim, D. K. Jin, H. S. Kim, M.-S. Shin, T. H. Ahn, I. S. Choi, and E. K. Shin Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients J. Am. Coll. Cardiol., September 3, 2003; 42(5): 905 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Stenvinkel, R. Pecoits-Filho, and B. Lindholm Coronary Artery Disease in End-Stage Renal Disease: No Longer a Simple Plumbing Problem J. Am. Soc. Nephrol., July 1, 2003; 14(7): 1927 - 1939. [Full Text] [PDF]
|
|
|
|
 |
|
 W.J. Remme Reconsider the management of all coronary artery disease patients: Importance of the EUROPA trial Eur. Heart J. Suppl., July 1, 2003; 5(suppl_E): E23 - E30. [Abstract] [PDF]
|
|
|
|
 |
|
 B. M. Singh and J. L. Mehta Interactions Between the Renin-Angiotensin System and Dyslipidemia: Relevance in the Therapy of Hypertension and Coronary Heart Disease Arch Intern Med, June 9, 2003; 163(11): 1296 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Galle, A. Mameghani, S.-S. Bolz, S. Gambaryan, M. Gorg, T. Quaschning, U. Raff, H. Barth, S. Seibold, C. Wanner, et al. Oxidized LDL and its Compound Lysophosphatidylcholine Potentiate AngII-Induced Vasoconstriction by Stimulation of RhoA J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1471 - 1479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Amann, C. Ritz, M. Adamczak, and E. Ritz Why is coronary heart disease of uraemic patients so frequent and so devastating? Nephrol. Dial. Transplant., April 1, 2003; 18(4): 631 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Von der Thusen, J. Kuiper, T. J. C. Van Berkel, and E. A. L. Biessen Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential Pharmacol. Rev., March 1, 2003; 55(1): 133 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Oldgren, L Wallentin, L Grip, R Linder, B.L Norgaard, and A Siegbahn Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease Eur. Heart J., January 1, 2003; 24(1): 86 - 93. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Yan, D. Kim, T. Aizawa, and B. C. Berk Functional Interplay Between Angiotensin II and Nitric Oxide: Cyclic GMP as a Key Mediator Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): 26 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Landmesser and H. Drexler Oxidative stress, the renin-angiotensin system, and atherosclerosis Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A3 - A7. [Abstract] [PDF]
|
|
|
|
|
|
N. Werner and G. Nickenig AT1 receptors in atherosclerosis: biological effects including growth, angiogenesis, and apoptosis Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A9 - A13. [Abstract] [PDF]
|
|
|
|
|
|
R. De Caterina and C. Manes Inflammation in early atherogenesis: impact of ACE inhibition Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A15 - A24. [Abstract] [PDF]
|
|
|
|
|
|
B. Schieffer Interaction of interleukin-6 and angiotensin II in atherosclerosis: culprit for inflammation? Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A25 - A30. [Abstract] [PDF]
|
|
|
|
|
|
V. Schachinger and A. M. Zeiher Atherogenesis--recent insights into basic mechanisms and their clinical impact Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2055 - 2064. [Full Text] [PDF]
|
|
|
|
|
|
K. D. O'Brien, D. M. Shavelle, M. T. Caulfield, T. O. McDonald, K. Olin-Lewis, C. M. Otto, and J. L. Probstfield Association of Angiotensin-Converting Enzyme With Low-Density Lipoprotein in Aortic Valvular Lesions and in Human Plasma Circulation, October 22, 2002; 106(17): 2224 - 2230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Bermudez, N. Rifai, J. Buring, J. E. Manson, and P. M. Ridker Interrelationships Among Circulating Interleukin-6, C-Reactive Protein, and Traditional Cardiovascular Risk Factors in Women Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1668 - 1673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Brasier, A. Recinos III, and M. S. Eledrisi Vascular Inflammation and the Renin-Angiotensin System Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1257 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hilfiker, D. Hilfiker-Kleiner, M. Fuchs, K. Kaminski, A. Lichtenberg, H.-J. Rothkotter, B. Schieffer, and H. Drexler Expression of CYR61, an Angiogenic Immediate Early Gene, in Arteriosclerosis and Its Regulation by Angiotensin II Circulation, July 9, 2002; 106(2): 254 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.D. Pradhan and P.M. Ridker Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur. Heart J., June 1, 2002; 23(11): 831 - 834. [Full Text] [PDF]
|
|
|
|
|
|
G. Plenz, H. Eschert, M. Erren, T. Wichter, M. Bohm, M. Flesch, H. H. Scheld, and M. C. Deng The interleukin-6/interleukin-6-receptorsystem is activated in donor hearts J. Am. Coll. Cardiol., May 1, 2002; 39(9): 1508 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ambrose and E. E. Martinez A New Paradigm for Plaque Stabilization Circulation, April 23, 2002; 105(16): 2000 - 2004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kramer, J. Sunkomat, J. Witte, M. Luchtefeld, M. Walden, B. Schmidt, R. H. Boger, W.-G. Forssmann, H. Drexler, and B. Schieffer Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179 Circ. Res., April 19, 2002; 90(7): 770 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D J Brull, J Sanders, A Rumley, G D Lowe, S E Humphries, and H E Montgomery Impact of angiotensin converting enzyme inhibition on post-coronary artery bypass interleukin 6 release Heart, March 1, 2002; 87(3): 252 - 255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hilfiker-Kleiner, A. Hilfiker, B. Schieffer, D. Engel, D. L Mann, K. C Wollert, and H. Drexler TNF{alpha} decreases {alpha}MHC expression by a NO mediated pathway: role of E-box transcription factors for cardiomyocyte specific gene regulation Cardiovasc Res, February 1, 2002; 53(2): 460 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Nickenig and D. G. Harrison The AT1-Type Angiotensin Receptor in Oxidative Stress and Atherogenesis: Part II: AT1 Receptor Regulation Circulation, January 29, 2002; 105(4): 530 - 536. [Full Text] [PDF]
|
|
|
|
|
|
G. Nickenig and D. G. Harrison The AT1-Type Angiotensin Receptor in Oxidative Stress and Atherogenesis: Part I: Oxidative Stress and Atherogenesis Circulation, January 22, 2002; 105(3): 393 - 396. [Full Text] [PDF]
|
|
|
|
|
|
M. Ruiz-Ortega, O. Lorenzo, M. Ruperez, V. Esteban, Y. Suzuki, S. Mezzano, J.J. Plaza, and J. Egido Role of the Renin-Angiotensin System in Vascular Diseases: Expanding the Field Hypertension, December 1, 2001; 38(6): 1382 - 1387. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Lindmark, E. Diderholm, L. Wallentin, and A. Siegbahn Relationship Between Interleukin 6 and Mortality in Patients With Unstable Coronary Artery Disease: Effects of an Early Invasive or Noninvasive Strategy JAMA, November 7, 2001; 286(17): 2107 - 2113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D.J. Brull, H.E. Montgomery, J. Sanders, S. Dhamrait, L. Luong, A. Rumley, G.D.O. Lowe, and S.E. Humphries Interleukin-6 Gene -174G>C and -572G>C Promoter Polymorphisms Are Strong Predictors of Plasma Interleukin-6 Levels After Coronary Artery Bypass Surgery Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1458 - 1463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Keidar, R. Heinrich, M. Kaplan, T. Hayek, and M. Aviram Angiotensin II Administration to Atherosclerotic Mice Increases Macrophage Uptake of Oxidized LDL: A Possible Role for Interleukin-6 Arterioscler Thromb Vasc Biol, September 1, 2001; 21(9): 1464 - 1469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. G. Laszik, X. J. Zhou, G. L. Ferrell, F. G. Silva, and C. T. Esmon Down-Regulation of Endothelial Expression of Endothelial Cell Protein C Receptor and Thrombomodulin in Coronary Atherosclerosis Am. J. Pathol., September 1, 2001; 159(3): 797 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. U. Chae, R. T. Lee, N. Rifai, and P. M. Ridker Blood Pressure and Inflammation in Apparently Healthy Men Hypertension, September 1, 2001; 38(3): 399 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Sakamoto, M. Aikawa, C. C. Hill, D. Weiss, W. R. Taylor, P. Libby, and R. T. Lee Biomechanical Strain Induces Class A Scavenger Receptor Expression in Human Monocyte/Macrophages and THP-1 Cells : A Potential Mechanism of Increased Atherosclerosis in Hypertension Circulation, July 3, 2001; 104(1): 109 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. G. Neri Serneri, M. Boddi, L. Poggesi, I. Simonetti, M. Coppo, M. L. Papa, G. F. Lisi, M. Maccherini, R. Becherini, A. Boncompagni, et al. Activation of cardiac renin-angiotensin system in unstable angina J. Am. Coll. Cardiol., July 1, 2001; 38(1): 49 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Munford Statins and the Acute-Phase Response N. Engl. J. Med., June 28, 2001; 344(26): 2016 - 2018. [Full Text] [PDF]
|
|
|
|
|
|
S. Blankenberg, H. J. Rupprecht, C. Bickel, C. Espinola-Klein, G. Rippin, G. Hafner, M. Ossendorf, K. Steinhagen, and J. Meyer Cytomegalovirus Infection With Interleukin-6 Response Predicts Cardiac Mortality in Patients With Coronary Artery Disease Circulation, June 19, 2001; 103(24): 2915 - 2921. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wassmann, U. Laufs, A. T. Baumer, K. Muller, K. Ahlbory, W. Linz, G. Itter, R. Rosen, M. Bohm, and G. Nickenig HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species Hypertension, June 1, 2001; 37(6): 1450 - 1457. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||